Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 4, 2001, Pages 463-473

  Cornillie, F ^a,d   Shealy, D ^a   D'Haens, G ^a,b   Geboes, K ^b   Van Assche, G ^b   Ceuppens, J ^b   Wagner, C ^a   Schaible, T ^a   Plevy, S E ^c   Targan, S R ^c   Rutgeerts, P ^b  

^a CENTOCOR INC   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d Department of Immunology ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFECT; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE FUNCTION; MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; CYTOKINES; DOUBLE-BLIND METHOD; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; LYMPHOCYTE COUNT; NEUTROPHILS; T-LYMPHOCYTES;

EID: 17744373658     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00956.x     Document Type: Article

References (14)

1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
2. Infliximab for the treatment of fistulas in patients with Crohn's disease
3. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
4. A role for TNFα mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease
5. Endoscopic and histological healing with infliximab tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
6. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor
7. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
8. Infliximab treatment benefits correlate with pharmacodynamic parameters in Crohn's disease patients
9. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation
10. Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions
11. Treatment of Crohn's disease with 6-mercaptopurine
12. Treatment with monoclonal antitumor necrosis factor α antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis
13. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease
14. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis